title: [Effect of Xuezhikang on cardiac function, serum C-reactive protein and blood lipid in patients with chronic heart failure].
abstract: OBJECTIVE
  To evaluate the effect of Xuezhikang (XZK) on cardiac function and serum C-reactive protein (CRP) in patients with chronic heart failure (CHF).
  
  
  METHODS
  Sixty-eight CHF patients were randomly assigned to two groups, the control group (30 cases) treated with angiotensin converting enzyme inhibitor, beta-receptor inhibitor, digoxin and diuretic, and the treated group (38 cases) with the above treatment plus XZK for six months. The changes of cardiac function and serum CRP level were measured by echocardiography and enzyme-linked immunosorbent assay (ELISA) respectively before and after treatment.
  
  
  RESULTS
  Compared with those before treatment, the NYHA cardiac function grade, the left ventricular dimension end diastole (LVDd), and the left ventricular dimension end systole (LVDs) decreased significantly (P < 0.05), and the ejection fraction (EF) and E/A ratio increased significantly in both groups after treatment (P < 0.05) , however, the decrement or increment was more significant in the treated group than that in the control group respectively (P < 0.05); the serum CRP level decreased significantly in the treated group after treatment and showed a level obviously lower than that in the control group (P < 0.05), which changed insignificantly after treatment.
  
  
  CONCLUSIONS
  Xuezhikang could improve cardiac function and decrease serum CRP level at the same time.
authors: Department of Cardiology, Shandong Provinical Hospital, Shandong University, Jinan.
authors: Zun-qi
authors: ZQ
authors: Liu
authors: Lian-qun
authors: LQ
authors: Cui
authors: Yong
authors: Y
authors: Wang
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D004077:Digoxin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004365:Drugs, Chinese Herbal; D008074:Lipoproteins; C030104:lipoprotein cholesterol; C496822:xuezhikang; D004077:Digoxin; D002097:C-Reactive Protein; D002784:Cholesterol